AUPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Aurinia Pharmaceuticals Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$16.49−0.02 (-0.12%)
Close on Oct 19, 2026
- Market cap
- $2.20B
- P/E (TTM)
- 7.2
- Dividend yield
- –
Aurinia Pharmaceuticals Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product sales | $79.41M | $73.56M | $74.17M | $70.63M | $66.57M | $59.97M | $57.58M | $55.50M | $55.03M | $48.07M | $42.32M | $40.78M | 95.4% | +19.3% |
| License, collaboration and royalty revenue | $3.81M | $4.14M | $2.94M | $2.84M | $3.43M | $2.49M | $2.29M | $12.27M | $2.16M | $2.23M | – | – | 4.6% | +10.9% |
| License, collaboration, and royalty revenue | – | – | – | – | – | – | – | $12.27M | $2.16M | $2.23M | – | $13.73M | – | – |
By region
From the segment and revenue-disaggregation notes of Aurinia Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.